RICHMOND, Calif. — Constance Therapeutics, a whole-plant cannabis extract producer, today announced that Dr. Arno Hazekamp, a world-renowned leader in cannabis research, will offer his expertise to the coordination of the company’s new research.
The study will explore the benefits whole-plant cannabis extracts may offer athletes suffering from chronic pain due to sports-related injuries. Undertaken by Constance Therapeutics in partnership with Gridiron Cannabis Coalition (GCC), the study aims to drive a new era of care for athletes – Care 2.0 – in which whole-plant cannabis extracts are utilized as part of an integrative or alternative treatment option to traditional pharmaceutical medications.
“The subject of cannabis as a modern medicine has been an interest of mine for more than a decade,” said Dr. Hazekamp. “It is of utmost importance that science and standards play significant roles in the development of medicinal cannabis as a form of treatment. The Constance Therapeutics/GCC study will provide the scientifically validated information necessary to determine the benefits of cannabis as a treatment option for athletes, and I look forward to being involved in the research.”
The Constance Therapeutics/GCC study will be based on the understanding that whole-plant cannabis oils from the female cannabis plant (not hemp) are more effective than isolated compounds, such as CBD only. It will take into account the necessity of tetrahydrocannabinol (THC) for optimal benefit, as indicated by “The Entourage Effect,” and will allot the appropriate amount of time and resources required to truly determine the potential cannabis oils have to offer sports-related injuries.
“The Constance Therapeutics/GCC study on cannabis and pain will greatly benefit from Dr. Hazekamp’s strong background and excellent reputation in medicinal cannabis research, and all of us at GCC are very pleased to have him on board,” said Eugene Monroe, NFL tackle and Gridiron Cannabis Coalition supporter. “As I have said, neither I nor GCC will ever stop pushing for acceptance of medicinal cannabis as a viable option for pain management, whether that acceptance comes first from the U.S. Government or the National Football League. Nobody should have to resort to harmful, addictive opioids for pain relief. We believe in the work that Constance Therapeutics is doing and look forward to our study commencing this summer.”
Dr. Hazekamp is a medicinal cannabis advocate and expert on standardized growing, quality control and product development. He obtained his bachelor’s degree in molecular biology, as well as his master’s degree in biopharmaceutical sciences from Leiden University in the Netherlands. His doctorate work was focused on the medicinal properties of cannabis and the practical obstacles that stand between the plant and its development into a modern medicine. Dr. Hazekamp was actively involved in setting up the medicinal cannabis program of the Dutch Health Ministry, and he became a strong advocate of a more science-based approach to the medicinal use of cannabis in the Netherlands and abroad.
“I recently attended Dr. Hazekamp’s Masterclass on medicinal cannabis in the Netherlands. This once-in-a-lifetime experience and the breadth of knowledge that he shared confirmed that Dr. Hazekamp was the ideal partner to assist with the coordination of our study,” said Constance Finley, founder and CEO of Constance Therapeutics. “Dr. Hazekamp’s expertise will be invaluable to our research, and his perspectives on science-based medicinal cannabis perfectly align with the values of Constance Therapeutics. We are greatly looking forward to working with him.”
About Constance Therapeutics
Constance Therapeutics is a vertically integrated medicinal cannabis company producing standardized and science-based whole-plant cannabis extracts. The company has created a new category of whole-plant cannabis extracts that fills the gap between traditional pharmaceuticals and commonplace cannabis products, providing much needed additional treatment options to physicians and their patients. Constance Therapeutics’ extracts are derived from fully trimmed, female unfertilized cannabis sativa flowers of plants with known genetics using certified-organic, pharmaceutical-grade ethanol via a highly controlled, quantitatively-defined and patented process that is based on solid scientific and engineering principles. Extracts are systematically third-party tested and routinely cross-tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in Richmond, California, Constance Therapeutics’ cannabis extracts are available exclusively for therapeutic use and can only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, please visit: www.constancetherapeutics.com.
McGrath/Power Public Relations for Constance Therapeutics
Allyson Scott, 408-727-0351